NATALIE BRADSHAW: Open Payments
NPI 1871275024 · FLORENCE, MS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,188 in 112 payments from 25 companies in 2025. Trend: 2023 $205 · 2024 $1,180 · 2025 $2,188
Food & beverage: $2,183Education: $4
| Company | Payments | Amount |
|---|---|---|
| Corcept Therapeutics | 23 | $317 |
| Lilly USA, LLC | 17 | $291 |
| Bayer Healthcare Pharmaceuticals Inc. | 12 | $266 |
| Novo Nordisk Inc | 12 | $208 |
| Astellas Pharma US Inc | 3 | $149 |
| Xeris Pharmaceuticals, Inc. | 5 | $116 |
| AstraZeneca Pharmaceuticals LP | 6 | $102 |
| Tandem Diabetes Care, Inc. | 6 | $102 |
| RGH Enterprises LLC | 1 | $93 |
| Esperion Therapeutics, Inc. | 5 | $78 |
Products named: Korlym, Kerendia, MOUNJARO, Veozah, RECORLEV, FARXIGA, t:slim X2 Insulin Pump with Control-IQ, NEXLETOL.
Industry payments across MS — which companies pay providers there.
